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Abstract
Mammalian airways are protected from infection by a thin film of airway surface liquid (ASL) which
covers airway epithelial surfaces and acts as a lubricant to keep mucus from adhering to the epithelial
surface. Precise regulation of ASL volume is essential for efficient mucus clearance and too great a
reduction in ASL volume causes mucus dehydration and mucus stasis which contributes to chronic
airway infection. The epithelial Na+ channel (ENaC) is the rate-limiting step that governs Na+
absorption in the airways. Recent in vitro and in vivo data have demonstrated that ENaC is a critical
determinant of ASL volume and hence mucus clearance. ENaC must be cleaved by either intracellular
furin-type proteases or extracellular serine proteases to be active and conduct Na+, and this process
can be inhibited by protease inhibitors. ENaC can be regulated by multiple pathways, and once
proteolytically cleaved ENaC may then be inhibited by intracellular second messengers such as
cAMP and PIP2. In the airways, however, regulation of ENaC by proteases seems to be the
predominant mode of regulation since knockdown of either endogenous serine proteases such as
prostasin, or inhibitors of ENaC proteolysis such as SPLUNC1, has large effects on ENaC activity
in airway epithelia. In this review, we shall discuss how ENaC is proteolytically cleaved, how this
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process can regulate ASL volume, and how its failure to operate correctly may contribute to chronic
airway disease.
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Introduction
The epithelial Na+ channel (ENaC) is expressed in the apical plasma membrane of several
tissues including the colon, kidney, and lung and constitutes the rate-limiting step for Na+
absorption [84,122]. ENaC in the airways is distinguished from ENaC expressed in other
tissues by insensitivity to aldosterone [136]. Instead, ENaC in airway epithelia is regulated by
glucocorticoids and so its expression is linked to changes in inflammation rather than changes
in blood pressure/volume [136,151]. ENaC can also be controlled by intracellular factors
including pH, lipids (PIP2 and PIP3), and protein kinase A [91,112,166] which may affect the
number of ENaCs inserted into the plasma membrane as well as affect gating [91,156,166].
The conducting airways are the primary interface between the extracellular environment and
the lung and play a major role in host defense [9,34,48]. Mucus clearance is a central component
of the innate defense system of the lung [35,76]. During normal mucus clearance, inhaled
pathogens and particles become trapped in the mucus layer and are then expelled before they
can colonize the airways [30]. The mucus layer is of variable height, and mucus is kept away
from the predominantly ciliated airway epithelia by the presence of a ~7 µm periciliary liquid
layer which, as the name suggests, surrounds the beating cilia and acts as a lubricant to keep
mucus away from the epithelial cell surface. Together, these layers make up the airway surface
liquid (ASL) [14]. The rate of mucociliary clearance is strongly influenced by the hydration
state of the ASL and mucus layers [142]. Mucus hydration is set by the volume of liquid present
on airway surfaces, which in turn may be modified by active ion transport processes in both
the superficial epithelium and glands [7,14,157,159]. Secretion is mediated by the apical
membrane Cl− channels TMEM16A and CFTR [3,47] whilst absorption requires ENaC
[123]. Intracellular second messengers play a large role in regulating these channels [3,47,
63,85,90,112]. However, in the last decade, soluble and epithelial membrane bound proteases
have been found to regulate ENaC, which has opened up a whole new avenue of research
[122,123]. Channel-activating protease 1 (CAP1; prostasin) was first identified in Xenopus
laevis oocytes [150] and, subsequently, CAP2 (transmembrane protease serine 4 [TMPRSS4]),
CAP3 (matriptase or epithin), and human neutrophil elastase [22] as well as trypsin [150] were
all found to activate ENaC. This review will focus on recent discoveries regarding the ability
of these proteases and their inhibitors to affect ASL volume by varying the ENaC activity and
on their potential clinical significance.
Structure of ENaC and non-proteolytic regulation
ENaC consists of three separate subunits termed α, β, and γ that are ~30% homologous to each
other. These subunits form a channel that is highly selective for Na+ over K+ and is
characterized by sensitivity to amiloride in the submicromolar range [122,123]. Each subunit
is composed of a large extracellular loop, which has been likened to a hand (Fig. 1). In addition,
ENaC also has two transmembrane domains termed M1 and M2, respectively, and two short
intracellular tails (Fig. 1). Site-directed mutagenesis has revealed that residues in the pre-M2
region of α, β, and γENaC subunits affect the channel conductance and amiloride binding
[126]. Based on the recent crystal structure of the related acid-sensing channel (ASIC), the
issue of ENaC subunit stoichiometry appears to be settled with ENaC presumably consisting
of a 1α:1β:1γ complex [69]. However, ASIC is a homotrimer, and previous functional studies
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with ENaC subunits have suggested a heterotetrameric or even variable stoichiometry [2,41,
80,133]. When the αENaC subunit is injected into Xenopus oocytes alone, ~2% of current is
seen relative to α, β, γENaC co-expression. In contrast, when the α, β or α, γ subunit
combinations are co-injected, up to 15% of full activity is seen. The β or γ subunits do not
produce currents when expressed alone and β, γ together induce ~2% of full activity, but only
at several days post-injection [12]. Mueller et al. have reported that the C-terminus of αENaC
plays a critical role in permitting exit of this channel from the endoplasmic reticulum [97].
Thus, αENaC may have an essential role in bringing the β and γ subunits to the plasma
membrane, while the β and γ subunits are essential for stabilization of the multimer in the
plasma membrane.
In addition to the well-characterized α, β, and γ subunits, a fourth ENaC subunit, termed δ, has
been described [18,155]. δENaC is highly expressed in the testis, ovary, pancreas, and brain
and is also expressed in the nasal epithelium. The δENaC subunit shares considerable sequence
similarity with the α subunit and forms functional ion channels together with the β and γ
subunits in pancreas, testes, ovaries, and brain and in smaller amounts in heart, placenta, lung,
liver, kidney, thymus, prostate, colon, and lymphocytes [8,18,71,155,161]. In Xenopus oocytes,
expression of δ, β, γENaC results in an approximately tenfold increase in amiloride-sensitive
current compared to α, β, γENaC. Consequently, differential expression of the α and δ subunits
may provide an additional way of regulating ENaC activity and the δ subunit seems to promote
constitutive cleavage of the γ subunit, which may favor the presence of active channels at the
cell surface [56]. Thus, replacement of the α subunit with the δ subunit in the heterotrimeric
channel may favor the constitutive activation of ENaC and may reduce the pool of near-silent
plasma membrane channels that can be activated by extracellular proteases [56].
ENaC gating kinetics are characterized by long opening and closing times, [113] and structural
studies have revealed two regions that are important for gating. The HG motif, so named
because it possesses a glycine and a histidine in the amino terminus, is present in every ENaC/
degenerin family member known to conduct ions and is involved in channel opening. Mutation
of this residue in the βENaC subunit causes pseudohypoaldosteronism, a disease characterized
by inactivity of ENaC [73,134]. The DEG gating domain in the extracellular loop, close to the
M2 region, was first described in degenerins channels of Caenorhabditis elegans, which are
related to ENaC, and involves a critical serine residue [126]. Mutations in this region cause an
increase in the open probability [72,129].
Regulation of ENaC by intracellular 2nd messengers
Although it is perhaps surprising that ENaC is the sole ion channel responsible for apical
Na+ entry into airway epithelial cells, it is clear that this channel can undergo multiple modes
of regulation. For example, in addition to being cleaved and activated by several different types
of proteases, ENaC can also be regulated by intracellular second messengers. In non-cystic
fibrosis (CF) human airways, ENaC is inactivated by agonists that raise cAMP, such as
adenosine, forskolin, or isoproterenol [16,75,78]. In CF airways, which lack functional CFTR,
increases in cAMP stimulate ENaC [16,75,78], suggesting that CFTR acts to limit ENaC
activity in the airways. Using the patch clamp technique, Stutts et al. demonstrated that CFTR
expression directly altered ENaC sensitivity to forskolin-induced changes in intracellular
cAMP/PKA [137,138]. Using the Xenopus oocyte expression system, it was reported that the
intracellular domains of CFTR directly interacted with ENaC sufficiently to alter ENaC’s
sensitivity to cAMP [70,86,127]. However, since CFTR and ENaC are linked to the
cytoskeleton, there may also be indirect interactions between these two ion channels [10,68,
102].
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A reduction in the intracellular Cl− concentration following stimulation of either CFTR or ClC
Cl− channels has also been reported to lower ENaC activity, suggesting that ENaC is regulated
by the intracellular Cl− concentration [6,70,96]. Despite a precedence for this type of regulation
of ENaC in mouse salivary duct epithelia [32], this hypothesis remains to be tested in the
airways, and other investigators using Xenopus oocytes have reported that ENaC is still
regulated appropriately following co-injection of αβγENaC and a non-Cl-conducting CFTR
mutant [139]. The interaction between these two ion channels may be variable, and in the sweat
glands, where Cl− absorption rather than Cl− secretion occurs under basal conditions, ENaC
is activated in parallel with CFTR rather than being inactivated [115]. Surprisingly, more than
20 years after the initial discovery that ENaC’s sensitivity to cAMP is CFTR dependent, the
molecular basis underlying this phenomenon has not been fully understood.
Activation of P2Y2 receptors on the apical membrane of airway epithelial cells with ATP or
UTP raises intracellular IP3 and Ca2+, in parallel with a fall in intracellular PIP2 [36]. These
changes then stimulate Ca2+-mediated Cl− secretion and inhibit ENaC-mediated Na+
absorption [39,67,95]. The underlying Cl− channel has only recently been cloned and is likely
to be TMEM16A/Ano1 [25,60,128,162]. TMEM16A is sensitive to changes in intracellular
Ca2+ levels [25,128,162]. However, ENaC is not directly Ca2+ sensitive and instead is activated
by anionic lipids [91,165]. Phosphatidylinositol 4,5-bisphosphate (PIP2), phosphatidylinositol
3,4,5-trisphosphate (PIP3), and phosphatidylserine were shown to prevent ENaC run-down in
excised patches of plasma membrane [91] and PIP2 was shown to bind to all the three ENaC
subunits [165], resulting in ENaC activation. Tong and Stockland demonstrated that the
epidermal growth factor receptor decreases plasma membrane PIP2 levels to inhibit ENaC
[148], whilst Kunzelmann et al. demonstrated that the stimulation of purinergic receptors
decreases PIP2 levels to inhibit ENaC [82]. PIP2 is the substrate that is used by phospholipase
C to form IP3 following stimulation of P2Y2-R [152]. In addition, numerous other regulators
of ENaC exist, including, but not limited to, the epidermal growth factor receptor [148],
endothelin receptors [52], epinephrine [110], as well as bacterial proteins and respiratory
viruses [83,87,132].
Types of proteases that can cleave ENaC
In contrast to intracellular 2nd messengers, which can affect either the number of ENaC
channels in the plasma membrane (n) or their open probability (Po), proteolytic cleavage of
ENaC is thought to have a greater effect on Po. Three different types of proteases have been
shown to cleave ENaC: (1) intracellular convertase-type proteases such as furin [64], (2)
extracellular, cell-attached proteases, which can either be membrane spanning (with either the
C or N terminus located intracellularly) [110] or glycosylphosphatidylinositol (GPI)-anchored
[150], and (3) soluble proteases including trypsin and neutrophil elastase [22,150]. A schema
of how proteases may cleave ENaC to increase Po is shown in Fig. 2, whilst an overview of
how ENaC may be cleaved by different proteases is shown in Fig. 3. Extracellular proteases
may be more influenced by changes in the ASL microenvironment, especially during chronic
airway disease, since the activity of these proteases can be affected by changes in ASL pH and/
or the presence of extracellular protease inhibitors. However, intracellular proteases may also
be affected by such changes as the lack of CFTR [103].
Furin-type proteases
Convertases are so named since they process precursor proteins into biologically active forms.
Furin is a Ca2+-dependent serine endoprotease that cleaves precursor proteins at their paired
basic amino acid processing sites [104]. The minimal consensus sequence for furin cleavage
is R/K-X-X-R where X is any amino acid [65]. Endogenous, furin-dependent intracellular
cleavage of ENaC was first suggested by Hughey et al. [64]. These investigators demonstrated
that expression of α, β, or γENaC alone in MDCK cells showed full-length subunits by Western
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blot (~93–96 kDa). In contrast, co-expression of these three subunits resulted in the appearance
of smaller ~65-kDa bands of α and γENaC subunits, but not the βENaC subunit, as well as the
full-length bands [64]. The mass of the α and γ fragments matched the predictions for cleavage
at two recognized furin sites in the α subunit and a single site in the γ subunit (see Fig. 1 for
the location of the furin cleavage sites). These investigators then demonstrated by mutagenesis
that cleavage of the α subunit had the greatest effects on macroscopic ENaC currents [65].
Paradoxically, cleavage of primarily the γ subunit by extracellular serine proteases also exerts
large effects on ENaC function, and the difference between these two findings has yet to be
explained [59]. Furin is predominantly located in the Golgi apparatus (Fig. 2). However, furin
family convertases may also be active at the cell surface and could theoretically cleave ENaC
whilst it is in or near the plasma membrane [147]. Thus, furin-dependent activation of ENaC
has been suggested to provide a pool of ENaCs, whose activity can be further modified by
membrane-associated CAPs and/or by intracellular second messengers such as PIP2 and PKA
[109].
GPI-anchored proteases
Serine proteases are named because at least one of the amino acids in their active site is a serine
and this does not refer to their target amino acid sequence, which can vary considerably
depending on the serine protease in question. The first channel-activating protease (CAP1)
discovered to activate ENaC was ultimately identified as murine prostasin (TMPRSS8)
[154], and human prostasin was found to similarly activate ENaC [44]. Co-expression of the
serine protease CAP1/prostasin, cloned from the Xenopus kidney epithelial cell line (A6 cells),
with ENaC in Xenopus oocytes, resulted in several fold increases in ENaC-mediated whole
cell currents [150]. Subsequently, prostasin has been soundly implicated by siRNA-mediated
knockdown [149] or by gene disruption in mice [111] in the regulation of ENaC in the lung.
Interestingly, this effect may not rely on extracellular CAP1 activity, because in other studies
catalytically inactive prostasin mutants fully stimulated ENaC [153]. However, incubation in
media containing the Kunitz-type serine protease inhibitor aprotinin prevented ENaC
activation by CAP1, perhaps indicating that CAP1 plays a noncatalytic role in a proteolytic
cascade that targets ENaC (see below) [150]. This study found no effect of CAP1 on the number
of channels at the plasma membrane, suggesting that CAPs increase ENaC activity by changing
the open probability (PO). Exogenous application of purified trypsin can mimic the actions of
CAPs by activating ENaC in the oocyte expression model [150].
The human ortholog of CAP1 was found to be prostasin [44], which was originally cloned
from bicarbonate-rich seminal fluid [164]. Prostasin is present in normal and CF airway
epithelia [44], and Tong et al. demonstrated that knockdown of prostasin in a CF airway
epithelial cell line lowered basal amiloride-sensitive current [149]. Since prostasin is GPI-
anchored, it is cleaved by GPI-specific phospholipase C and can be secreted in addition to
being membrane bound [29]. Thus, the (possibly indirect) activation of ENaC by prostasin may
be relieved if prostasin is itself cleaved by phospholipase C and removed from the airway
surface. While such a mode of regulation has been demonstrated in renal epithelia [140], it
remains to be tested in the airways. If this happens in the airways, PLC-dependent regulation
of ENaC may provide for an additional mode of regulation.
A polybasic stretch of residues in γ-ENaC was recently identified by mutagenesis as being
required for CAP1/prostasin stimulation of ENaC [19]. Interestingly, Bruns et al. [19] reported
that γ-ENaC processing occurs in oocytes expressing catalytically “dead” prostasin that could
not directly cleave proteins following site-directed mutagenesis. Furthermore, this protein is
maximally active at pH 9 and essentially inactive at pH 7 [164]. However, ASL pH is generally
thought to be ≤pH 7, suggesting that prostasin may not be proteolytically active in the airway
lumen [31]. Taken together, these data suggest that either (1) the catalytic mutant prostasin
Gaillard et al. Page 5













retains a portion of its protease activity or (2) prostasin may facilitate the activation of other
channel-activating protease(s) by means other than its proteolytic capability. What is left
unresolved from these studies, however, is the mechanism by which CAP1/prostasin stimulates
ENaC. Bruns et al. proposed that prostasin cleaves γ-ENaC at a polybasic tract (RKRK)
downstream from the γ-furin site and that prostasin worked in conjunction with furin to remove
an inhibitory peptide from the γ-ENaC extracellular domain [19]. Interestingly, it has now been
recognized that CAP1/prostasin stimulates ENaC independently of its own catalytic activity
[150,153]. Questions have been raised, but not settled, about the effectiveness of mutagenesis
of the prostasin catalytic triad as a maneuver to completely eliminate prostasin catalytic activity
[19], which would influence the interpretation of the earlier experiments. Most recently,
Svenningsen and colleagues found that plasmin binds to prostasin and that this interaction is
important for ENaC activation [140]. Although not tested or discussed by these authors,
perhaps this role of prostasin does not require its catalytic activity and could reveal that
prostasin plays multiple roles in proteolytic regulation of ENaC, either as a protease targeting
ENaC or as an anchor in a complex of ENaC and other proteases.
Trans-membrane serine proteases
ENaC is also regulated by a variety of type II membrane-bound serine proteases whose N-
termini are intracellularly located. CAP2 (TMPRSS4), CAP3 (matriptase), and human airway
trypsin-like protease are all expressed in the airways [146]. CAPs 2 and 3 are known to regulate
ENaC [153]. In contrast to CAP1, both CAP2 and CAP3 must possess catalytic activity to
stimulate ENaC [4]. CAP2 cleaves ENaC at multiple sites in all three subunits, including
cleavage at a conserved basic residue located in the vicinity of the degenerin site (α-K561, β-
R503, and γ-R515) [49]. Multiple sites including the furin consensus sites in αENaC (R205/
R231) and γENaC (R138) are responsible for the ENaC fragments observed in Xenopus oocytes
coexpressing CAP2 [49]. However, the only cleavage site absolutely required for channel
activation by CAP2 is the γENaC site R138 [49].
Soluble proteases
The first soluble serine protease shown to affect ENaC was trypsin [150]. Pretreatment with
this enzyme diminished the size of γ-ENaC from 87 kDa (full length) or 76 kDa (furin-cleaved)
to 67 kDa in Xenopus oocytes. Diakov et al. [40] found that cleavage of the γENaC subunit
was important for changes in overall ENaC conductance and that a single-point mutation at
position 181 (γK181A) removed the stimulatory effect of serine proteases [40]. Interestingly,
in oocytes expressing α, β, and γK181A ENaC, the 67-kDa band was present even in the
absence of extracellular trypsin, suggesting that this mutant was spontaneously cleaved and it
is likely that this mutation increases the specificity of γENaC for endogenous proteases.
However, when the furin-insensitive mutation was introduced into γENaC along with the
γK181Amutation (α, β, γP138A, K181AENaC), the gain of function associated with the
γK181A mutation alone was absent, indicating that cleavage at the furin site must occur before
cleavage at position 181 by serine proteases [40].
In Xenopus oocytes expressing α, β, γENaC or in airway epithelia natively expressing ENaC,
a brief exposure to the soluble serine protease neutrophil elastase increased amiloride-sensitive
currents approximately fivefold [22,58]. The effects of neutrophil elastase were not potentiated
by trypsin, suggesting that ENaC is maximally activated by either serine protease. Harris et al.
found that brief exposure of ENaC expressing Xenopus oocytes to neutrophil elastase generated
a new fragment of γ-ENaC in the surface pool, consistent with cleavage downstream of the γ-
ENaC furin site [58]. Elastase inhibitors prevented this effect and the elastase-induced fragment
appeared only in the pool of proteins biotinylated at the cell surface [58]. However, a
contemporaneous study identified the specific residues V182 and V193 in human γENaC as
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being essential for ENaC stimulation by human neutrophil elastase, a location consistent with
the γENaC fragment generated by elastase in ENaC-expressing Xenopus oocytes [49].
Mast cells can release soluble, chymotrypsin-like serine proteases [141], which may also be
able to activate ENaC [40]. However, little is known about the effect of this protease on ENaC
activity in the airways. In Xenopus oocytes expressing δ, β, γENaC, exposure to chymotrypsin
resulted in a twofold increase in whole cell current, which was less than the effect on α, β,
γENaC (fivefold), consistent with the hypothesis that δENaC is more likely to be constitutively
cleaved than αENaC [56]. The increase in whole-cell current following chymotrypsin
application coincided with the appearance of an approximately 20-kDa δENaC cleavage
fragment. Similar to αENaC, the δ subunit requires co-expression with the γENaC subunit for
activation by external proteases.
Proteolytic activation of near silent ENaC channels
It has been suggested that a subpopulation of ENaCs somehow bypass furin cleavage in the
Golgi apparatus, and following their insertion into the plasma membrane these channels display
very little or no activity. Accordingly, these channels have been termed ‘near silent’ ENaCs
(Fig. 3) [21]. Distinct, basally active, silent and/or near-silent ENaC populations were
distinguished by patch clamp [22]. The application of exogenous trypsin increased the open
probability of near-silent ENaC more than 50-fold in outside-out patch recordings, increasing
their activity towards that of basally active ENaCs [21]. Extensive washing did not reverse this
process, suggesting that the activation was irreversible, as one would expect after proteolytic
cleavage [21]. The increase in open probability occurred within seconds to several minutes
after application of trypsin and could be inhibited by soybean trypsin inhibitor [21]. Blockade
of trypsin-sensitive G proteincoupled proteinase-activated receptors did not affect the increase
in open probability of ENaC. Taken together, these results suggested a direct effect of trypsin
on Po [21,40].
In similar experiments, concentrations of neutrophil elastase aimed to reprise those seen in
diseased lungs increased the activity of near-silent ENaCs approximately 100-fold in patches
from mammalian NIH-3T3 fibroblast cells [22]. No significant effects of neutrophil elastase
were observed on basally active ENaCs, again suggesting that neutrophil elastase only activates
ENaCs which have not been cleaved. Trypsin exposure following neutrophil elastase did not
increase the amiloride-sensitive shortcircuit current further, suggesting that these proteases
share a common mode of action for increasing Na+ transport, likely through proteolytic
activation of ENaC. Great variability in the extent of ENaC stimulation by application of
exogenous proteases has been reported and partly reflects different extents of proteolytic
stimulation of ENaC existing in different experimental systems. In addition, varying extents
of proteolytic stimulation of ENaC or of Na+ absorption are consistent with the hypothesis that
both intracellular, aprotinin-insensitive activation of ENaC prior to membrane insertion and
extracellular activation of ENaC by serine proteases can occur. Since acute neutrophil elastase
exposure rapidly diminishes mucus clearance rates in sheep [124], it is possible that a reserve
of silent ENaCs exist in the plasma membrane of superficial airway epithelia under normal
physiological conditions.
The relative contributions of α vs. γ subunit cleavage to macroscopic
currents
The initial work of Hughey and Kleyman detected fragments of ENaC that matched the size
of fragments predicted to arise from cleavage at furin consensus sequences in α and γENaC
[64,66]. Moreover, mutagenesis of these sites to prevent cleavage by furin reduced basal ENaC-
mediated current which was then recovered by exogenous trypsin. The contributions of α and
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γ sites to this effect were disproportionate, with mutation of the cleavage sites in αENaC having
the greatest effect on macroscopic currents. Although the validity of these observations has
not been challenged (our unpublished data is the same), they are nonetheless difficult to
reconcile with the overall body of subsequent work on non-furin type serine proteases that
activate ENaC. For example, neutrophil elastase fully stimulates quiescent ENaC [22], and in
two independent studies cleavage of γENaC at specific residues was found to be the requisite
cleavage event for this activation [1,58]. Prostasin-mediated stimulation of ENaC was also
traced to cleavage of the γENaC subunit [19]. In addition, we reported that although CAP2 co-
expression with ENaC generated fragments of α-ENaC predicted by cleavage at its two furin
consensus sequences, mutation of those sites and prevention of cleavage was without effect on
CAP2 stimulation of ENaC. In contrast, preventing cleavage of γENaC at its consensus furin
sequence eliminated CAP2 activation of ENaC. Subsequently, much, if not all of the ability of
trypsin [40] and plasmin [105] to stimulate ENaC have been traced to cleavage of γENaC.
These findings with multiple non-furin serine proteases, each of which likely cleave ENaC
only at the cell surface, are difficult to reconcile with the demonstrated importance of the α-
subunit furin sites in earlier studies [26]. These findings clearly indicate that broad gaps in our
knowledge exist, and the data may indicate as-yet, poorly understood contributions of αENaC




In their seminal 1997 Nature paper, Vallet et al. [150] demonstrated that CAP1-dependent
activation of ENaC could be prevented by pretreatment with the 6.5-kDa protease inhibitor
aprotinin [150]. Bridges et al. found that, out of several serine protease inhibitors tested in
human airway epithelial cultures, only inhibitors containing naturally occurring Kunitz
domains inhibited ENaC currents [17]. Aprotinin, also known as bovine pancreatic trypsin
inhibitor, is a reversible Kunitz-type inhibitor of several serine proteases including trypsin and
CAPs 1–3 [123]. Using single-channel noise analysis, Adebamiro et al. found that aprotinin
caused an apparent decrease in the number of ENaC channels in the plasma membrane, which
accounted for the decrease in macroscopic ENaC currents [1]. In fact, the noise technique
correctly detected a decrease in the number of open (active) channels but could not recognize
that they were replaced by near-silent channels. The rates of onset and offset for inhibition of
ENaC by aprotinin and other protease inhibitors is much slower than for pore-blocking small
molecules such as amiloride. The reason for this difference is that protease inhibitors act to
prevent the conversion by proteolysis of uncleaved, near-silent ENaC to actively gating
channels. In this schema, the slow onset of aprotinin inhibition of ENaC-mediated current
reflects active channels being replaced by near-silent channels. The rate of onset of ENaC
current inhibition by aprotinin or other broad-specificity inhibitors is expected to approximate
the rate of retrieval of ENaC from the surface. Similarly, the gradual recovery from inhibition
by aprotinin likely reflects the rate of insertion of new ENaC channels into the plasma
membrane [123].
The Bayer pharmaceutical compound BAY 39–9437 is also a Kunitz-containing serine
protease inhibitor that is similar to placental bikunin. BAY 39–9437 is considered a potential
therapeutic agent for CF lung disease that would act by ameliorating the Na+ hyperabsorption
in CF airways. EPI-hNE4 (DX-890) is a low molecular mass (6.2 kDa) inhibitor of neutrophil
elastase that was modified from the second Künitz domain of inter-α-trypsin inhibitor [55,
118]. Replacement of the critical arginine residue at position 297 with an isoleucine makes this
domain a potent neutrophil elastase inhibitor that has been demonstrated to protect the lungs
of rats against neutrophil elastase and from CF sputum [38]. This compound also prevents
ENaC from being activated by neutrophil elastase, but not by trypsin or CAP1 [58].
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Serpins are a group of proteins first identified as protease inhibitors. The acronym serpin was
originally coined because many family members inhibited chymotrypsin-like serine proteases
[27]. The first members of the serpin superfamily to be extensively studied were the human
plasma proteins anti-thrombin and anti-trypsin, which play key roles in controlling blood
coagulation and inflammation, respectively [53]. SerpinE2, also known as protease nexin 1
(PN-1), has been shown to regulate Na+ absorption in airway epithelia [99]. Myerberg et al.
reported that PN-1 complexed with and inhibited prostasin on the apical surface of cultured
airway epithelia, leading to inhibition of Na+ absorption. Although PN-1 has been referred to
as the “cognate prostasin inhibitor”, Myerberg et al. discovered that PN-1 also inhibited
matriptase on the surface of airway epithelia [46]. Since matriptase can activate both prostasin
and ENaC, PN-1, and very likely other soluble, serpins are predicted to influence the proteolytic
regulation of ENaC.
Small molecule inhibitors
In addition to protein serine protease inhibitors, low molecular weight chemically synthesized
serine protease inhibitors have also been developed (125). Some of these inhibitors, including
camostat, have been shown to inhibit proteolytic activation of ENaC in vitro and in vivo [33].
Many covalent and noncovalent protease inhibitors have been developed as anticoagulators
[125]. While the effect of these compounds on ENaC activity is not currently known, they may
represent a library of potentially useful compounds that could inhibit ENaC in vivo.
Non-classical inhibitors of ENaC proteolysis
Short palate lung and nasal epithelial clone 1 (SPLUNC1) was recently identified as a regulator
of ENaC using a non-biased, proteomic screen designed to find ASL proteins capable of
interacting with serine proteases [50]. SPLUNC1 is a secreted protein of ~28 kDa which shares
homology with antibacterial proteins but has no obvious homology with Kunitz-type inhibitors
or serpins [11]. SPLUNC1 has previously been identified in human airway epithelial cultures
and this protein comprises up to 10% of the total protein content in their ASL [23]. SPLUNC1
was found to prevent ENaC proteolysis and inhibited ENaC-mediated currents in both
Xenopus oocytes and in human bronchial epithelial cultures [50]. In addition to being
structurally different from traditional protease inhibitors, which typically prevent cleavage of
ENaC, its mode of action also appears to differ. For example, despite preventing ENaC
proteolysis and activation by serine proteases such as trypsin, CAP1, and CAP2, SPLUNC1
does not inhibit protease activity directly and rather binds to ENaC, preventing it from being
cleaved [50]. SPLUNC1 also reduces basal ENaC currents in Xenopus oocytes [50], and
SPLUNC1 may actually reduce the number of ENaCs that are inserted into the plasma
membrane, thus reducing both basal ENaC activity and the number of ENaCs that are available
for proteolytic cleavage [121]. Whilst the nature of this internalization remains to be elucidated,
SPLUNC1 has several predicted adaptor protein binding-domains. Such adaptor proteins have
previously been shown to play a role in the internalization of ENaC [130,158] and may be for
a macromolecular complex with SPLUNC1 and α,β,γENaC to facilitate ENaC’s
internalization.
Regulation of ASL volume by ENaC, extracellular proteases, and anti-
proteases
Airway epithelial cells constitutively release extracellular purine nucleotides including ATP
and UTP at levels sufficient to activate P2Y2 receptors on the apical membrane, which stimulate
rises in intracellular IP3 and Ca2+, in parallel with a fall in intracellular PIP2 [36]. ATP can
also be broken down to adenosine (ADO) by a series of extracellular enzymes including the
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5’ ectonucleotidase CD73, and ADO can then stimulate A2B–R to raise cAMP which can
activate CFTR and also regulate ENaC [88,89,106–108]. However, based on the observation
that ENaC is basally active, airway epithelia were thought to be primarily absorptive, with little
or no gradient for Cl− secretion, even when CFTR was activated [13]. Furthermore, Cl−
secretion was only predicted to occur when ENaC was inhibited by molecules such as
amiloride, which would hyperpolarize the apical membrane and provide an electrical gradient
for Cl− secretion against the unfavorable chemical gradient [Clo− ~130 mM; Cli− ~40 mM]
[13]. These initial studies were performed under “thick film conditions” where ASL was
washed away and replaced with unphysiologically large volumes of Ringer solution. Thus,
whilst the native ASL volume on a 1 cm2 airway epithelial culture is measured in microliters,
such a culture may be bathed in up to 10 ml of Ringer solution during the course of an Ussing
chamber-type experiment. However, studies of ASL volume regulation under thin film
conditions, where native ASL is preserved, have demonstrated that ENaC can be spontaneously
inactivated, permitting Cl− (and liquid) secretion to occur. For example, Widdicombe et al.
demonstrated that ASL secretion could be induced in freshly excised bovine trachea [160].
Similarly, we have shown that purine nucleotides and nucleosides induced ASL secretion in
the absence of pre-inhibition of ENaC with amiloride [142,145]. These nucleotides and
nucleosides may act as soluble volume sensors whose concentration or dilution can directly
regulate ASL volume by changing the rates of Cl− secretion [120,143,145]. Whilst changes in
nucleotides/nucleosides have been shown to directly affect ENaC under closed-circuit
conditions, when these compounds are directly applied by the investigator at relatively high
micromolar concentrations, it seems under open circuit/thin film conditions when endogenous
ATP and ADO are much lower, and closer to concentrations seen in vivo (i.e., nanomolar
levels) that ENaC is primarily under the control of the protease/protease inhibitor system
despite the presence of endogenous ATP and ADO [50,144,146].
Human airway epithelial cultures were found to shift their phenotype from predominantly
absorptive when excess solution was added to the culture surface to predominantly secretory
when ASL height was similar to ciliary height (i.e., ~7 µm) [144]. Building upon this
observation, further research indicated that ENaC was acutely sensitive to the overlying ASL
volume and was activated when ASL volume was raised [98,146], a termed coined “ASL
volume expansion” [98]. Following ASL volume expansion, it is likely that silent ENaCs
become rapidly activated, allowing for a rapid return to a 7 µm ASL height. Whilst ENaC is
not itself likely to be volume sensitive, washing cultures with Ringer solution resulted in a
brisk activation of ENaC, whilst allowing ASL to accumulate resulted in ENaC inhibition
[98,146]. Airway cultures express (1) membrane-attached serine proteases that are not affected
by washing and/or dilution and (2) soluble protease inhibitors that could be removed/diluted
[98,146]. Thus, based on these observations, it was proposed that when ASL volume is high,
soluble protease inhibitors are removed/diluted and ENaC is activated by cell-attached
proteases (Fig. 4a) [28]. This is analogous to the situation seen in Ussing chambers when ASL
is washed away or diluted by the Ringer solution which bathes the mucosal membrane. A
physiological parallel may occur following glandular secretions onto airway surfaces. In
contrast, when ASL is undisturbed, protease inhibitors are present in sufficient concentrations
to inhibit ENaC (Fig. 4b).
The importance of soluble protease inhibitors as volumesensing regulators of ENaC has
recently been confirmed and knockdown of the soluble ENaC inhibitor SPLUNC1 prevented
spontaneous, ASL volume-dependent inactivation of ENaC in human airway cultures [50]. In
the absence of SPLUNC1, ASL volume continued to be absorbed following the addition of a
test solution and was not slowed as ASL height approached 7 µm, resulting in ASL volume
collapse to CF-like levels [50]. These data indicate that SPLUNC1 plays a crucial role in ASL
volume regulation [50]. SPLUNC1 is most highly expressed in glands of the proximal airways
in vivo [11] which may reflect a more secretory phenotype of these regions. SPLUNC1 is less
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well expressed in the distal airways, consistent with Kilburn’s hypothesis that converging
airways need to absorb excess solution to maintain constant ASL height [74]. Importantly,
when soluble inhibitors or proteins such as SPLUNC1 increase their concentration in the ASL
sufficiently to inhibit ENaC, this will facilitate Cl− secretion by hyperpolarizing the apical
membrane, providing an electrical gradient for Cl− exit into the lumen [13]. Whether or not
other highly expressed protease inhibitors such as the secretory leukocyte peptidase inhibitor
can affect ENaC activity remains to be tested. However, other PLUNC family members that
are expressed in the airways, including SPLUNC2 and LPLUNC1, do not appear to inhibit
ENaC to the same degree as SPLUNC1 [121].
The majority of protease/protease inhibitor regulation dependent of ENaC occurs, by its nature,
at the non-genomic level. However, normal airway epithelia exposed to prolonged 24 h ASL
volume expansion showed increased prostasin expression [99]. This increase in prostasin
expression was more pronounced after 12 h of ASL volume expansion whereas the effect of
excess ASL on ENaC activation is immediate [98,146]. It is likely therefore that, whilst the
bulk of volume-induced ENaC regulation happens non-genomically, the epithelia also has an
extensive reserve capacity and can increase expression of proteins that activate ENaC if
required to do so.
ENaC and mucus clearance in vivo
The alveolar region of the lung has a surface area that is approximately the size of one side of
a tennis court (i.e., ~75 m2) vs. the proximal airways, which have a surface area comparable
to a tea towel (i.e., ~30 cm2). During this transition, there are 23 generations of airways, from
the respiratory bronchioles to the trachea. As ASL and mucus move up the respiratory tract,
excess liquid must be absorbed in a regulated fashion as two airways converge to keep ASL
height/volume relatively constant. Failure to absorb excess ASL would result in an increase in
ASL height with every generation of airways that would become greater than the diameter of
the airways within a few generations, something that is clearly not seen in vivo. This model of
regulated absorption was first proposed over 40 years ago by Kay Kilburn [74]. Kilburn’s
hypothesis predicts that regulated absorption is active throughout the airways to help remove
the excess liquid which occurs as two airways converge into one, and thus far is the only
proposed model of mucus clearance that accounts for the movement of liquid up the airways
vs. the huge reduction in surface area presented to this anterograde-moving liquid. Recently,
in vivo experiments have been performed that support this hypothesis. For example, acute
inhalation of the ENaC antagonists amiloride or Parion552, a highly specific ENaC antagonist
with a Kd 100 times greater than amiloride (~7 nM), acutely increased mucus clearance rates
in unanesthetized sheep [61,62]. The inhibition of ENaC with either of these compounds in
vivo likely results in an increase in mucus hydration followed by a speeding up of mucus
clearance rates. A similar correlation between mucus hydration and mucus transport rates has
previously been reported in vitro [144]. Protease inhibitors do not affect ENaC directly but
block activation of near-silent channels arriving at the cell surface leading to a decrease in
Na+ absorption. Inhalation of the serine protease inhibitor camostat decreases Na+ absorption
and increases mucus clearance rates in vivo, suggesting that ENaC is likely to be active and
proteolytically cleaved under normal physiological conditions in vivo [33]. As will be
discussed later, neutrophil elastase, which also cleaves and activates ENaC, acutely decreases
mucus clearance rates when inhaled, suggesting that ENaC can also be further activated beyond
normal levels to increase fluid absorption and decrease mucus clearance rates [124]. This data
also indicates that there is a pool of silent ENaCs that are present in the airways that are ready
to be activated by this enzyme. Since neutrophil elastase levels are elevated in both CF and
chronic obstructive pulmonary disease (COPD), an understanding of how this protease can
affect ENaC levels and mucus clearance rates is of particular interest in the treatment of these
diseases.
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The contribution of ENaC to airway disease
CF reflects a spectrum of more than 1,600 mutations in the cystic fibrosis conductance regulator
(CFTR) gene [37]. The CF gene product, CFTR, is an ATP-binding cassette family member
[117]. The most common mutation, which occurs on 70% of all CF chromosomes, is the
deletion of phenylalanine at position 508 of the CFTR protein, which is designated as ΔF508.
The ΔF508 CFTR protein has a folding defect and is retained by the quality control system in
the endoplasmic reticulum, falls short of the processing pathways, and is degraded by
endoplasmic reticulumassociated degradation. CFTR functions as an apical, cAMP-activated
chloride channel and thus the molecular pathogenesis of ΔF508 CFTR is reflected by the
absence of functioning CFTR proteins in the apical plasma membrane of airway epithelia.
Other mutations can produce a nonfunctioning CFTR Cl− channel at the apical membrane and/
or a mutant CFTR with abnormal ion permeation characteristics. Despite relatively simple
genetics, multiple mechanisms have been evoked to describe CF pathogenesis, beyond the lack
of the apical cAMP-regulated Cl− conductance. For example, defective HCO3− secretion
through CFTR has been suggested to cause abnormal mucin release, which may lead to mucus
obstruction in CF airways [51,114]. Furthermore, persistent airway inflammation and infection
may be caused by a lack of CFTR [57,92,100]. However, although not universally accepted,
an increasing body of evidence suggests that ASL volume regulation and mucociliary clearance
are abnormal in CF due to defective ion transport processes [15] (Fig. 4c, d). Thus, CF patients,
who exhibit Cl− hyposecretion, Na+ hyperabsorption, and reduced glandular secretions, have
reduced mucus clearance [119], which can be partially restored by inhalation of nebulized
hypertonic saline [43,45] or by inhalation of the ENaC antagonist amiloride [5,77]. In contrast,
adult patients with pseudohypoaldosteronism have downregulated rates of Na+ transport and,
consequently, an abundance of ASL which results in clearance rates greater than those seen in
either normal controls or CF patients [73]. Unlike CF patients, who lack ASL volume, it seems
that too much ASL does not compromise lung defense and pseudohypoaldosteronism patients
are infection-free in adulthood [73]. The importance of ENaC in maintaining mucus clearance
has recently been demonstrated (1) in a murine model overexpressing βENaC, which results
in a decrease in ASL volume and mucus clearance and the emergence of chronic inflammation
and lung disease [94], and (2) in sheep acutely exposed to neutrophil elastase, which results in
a rapid decrease in mucus clearance rates [124]. Perhaps surprisingly, patients with
Kartagener’s syndrome, who have immotile cila, exhibit near-normal rates of mucus clearance
[101,116]. This likely occurs in the face of an absence of ciliary beating due to increased rates
of cough clearance in these patients as compared to normal subjects. Airway epithelial cultures
derived from these patients undergo normal ASL volume homeostasis, suggesting that their
mucus is normally hydrated [146]. Taken together, these data suggest that, even in the absence
of beating cilia, mucus clearance can be preserved if the mucus layer is appropriately hydrated.
Boucher et al. first demonstrated that ENaC hyperactivity was at least in part due to abnormal
stimulation of Na+ absorption by cAMP/PKA in CF airway epithelia [16], something that was
subsequently confirmed by Mall et al. [93]. However, it is also possible that abnormal
proteolytic cleavage of ENaC contributes to Na+ hyper-absorption. Due to secondary defects,
which may include abnormal local pH environments and/or chronic inflammation, furin,
prostasin, and CAP2 have been shown to be upregulated in the absence of CFTR [99,103,
146]. This upregulation may contribute to a failure of CF airways to affect suitable ASL volume
regulation, leading to ASL volume collapse which is indicative of a failure of mucus clearance
in vivo. Evidence for this failure comes from studies performed under thin film conditions. For
example, the ENaC-mediated transepithelial potential difference in airway epithelial cultures
derived from non-CF donors was trypsin insensitive when ASL volume was high and ENaC-
led absorption was underway, indicating that ENaC was fully active. The potential difference
then spontaneously underwent a shift and became trypsin sensitive when ASL volume was
low, suggesting that ENaC had been inactivated by the cultures [146]. In contrast, ENaC in
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CF-derived airway cultures remained trypsin insensitive, irrespective of ASL volume status,
indicating a failure to regulate ENaC proteolysis. Interestingly, ENaCs in CF airway cultures
remained aprotinin sensitive, suggesting that the defect lies at the level of the protease/anti-
protease balance in the ASL and that CF ENaCs are inherently normal in their ability to be
proteolytically cleaved [146].
As mentioned above, ENaC retains the ability to be cleaved in CF airway epithelia in an
identical fashion to non-CF ENaCs. However, protease levels are elevated in diseased lungs,
which may lead to abnormal ENaC activity. For example, whilst healthy individuals do not
have detectable levels of neutrophil elastase in the airways [79], concentrations of active
neutrophil elastase in excess of 1 µM or 200 µg/ml have been reported in CF lungs [38,79].
Such an increase may occur not only in CF airway disease but also in COPD. Cigarette smoke
exposure can induce downregulation of CFTR [24,81], but as yet there is no evidence that
ENaC is hyperactive in COPD airways. However, the high concentrations of neutrophil elastase
measured in COPD airways make this a likely symptom of the disease. In addition, neutrophil
elastase may overwhelm the ability of endogenous Kunitz-type anti-proteases or SPLUNC1
to inhibit ENaC. It should also be noted that since Kunitz-type proteases inhibitors do not
inhibit neutrophil elastase and vice versa, therapies based around Kunitz-type anti-proteases
may not be fully effective at inhibiting ENaC in inflamed/diseased airways which have elevated
levels of neutrophil elastase.
ENaC-related therapies and clinical trials
In keeping with the hypothesis that abnormal CF airway ion transport results in mucus
dehydration, improving the hydration of CF airway surfaces with inhaled hypertonic saline has
been shown to improve lung function and decreases the number of acute exacerbations [43,
45]. However, since Na+ is the natural substrate for ENaC, these therapies have a relatively
short duration of action [145]. To improve hydration, either alone or in combination with
hypertonic saline, drugs directly blocking ENaC-mediated Na+ absorption are undergoing
clinical evaluation. Early trials using nebulized amiloride revealed mixed benefits for CF
patients [54,77], and it was suggested that a weak affinity of amiloride for its receptor and the
short half-life of amiloride (~10 min) [145] contributed to amiloride’s failure to consistently
improve lung function in the clinic. It is also possible that the therapeutic benefit of amiloride
was impeded by factors related to the chronic disease process such as the systematic destruction
of CF small airways and that preventive amiloride therapy initiated shortly after birth, when
CF lungs are structurally normal, may be the most effective treatment of CF lung disease
[54,77]. Support for this hypothesis was recently obtained in preclinical studies in βENaC-
overexpressing mice by comparing therapeutic effects of preventive versus late amiloride
treatment in this model of CF lung disease [167]. More recently, however, long-acting and
highly potent ENaC blockers have been developed which may circumvent the pharmacokinetic
limitations of amiloride [62]. As such, the compound Gilead GS9411, which is 100 times more
potent than amiloride, has completed a phase 1 CF clinical trial, although the results have yet
to be published (http://www.cff.org/treatments/Pipeline/).
In addition to ENaC antagonists, protease inhibitors may also be clinically effective. In a proof
of concept study, Coote et al. reported that inhibition of ENaC function by the Kunitz-type
serine protease inhibitor camostat increased mucus clearance [33]. This has led to a search for
low molecular weight protease inhibitors as potential pharmacological agents to modulate
ENaC function and improve mucociliary clearance and it may not be long before low molecular
weight Kunitz-type serine protease inhibitors enter phase 1 clinical trials. Neutrophil elastase
inhibitors have also been developed with a view towards inhibiting neutrophil elastase-induced
ENaC hyperactivity in the lung [58]. Inhibition of neutrophil elastase by specific inhibitors
may have additional beneficial effects on CF airways as this treatment will not only block
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ENaC activity but also prevent the detrimental effects of neutrophil elastase as mediator of
tissue inflammation and destruction. Future clinical trials may soon reveal the benefits of
elastase inhibitors in the treatment of CF patients.
Conclusions
Proteolytic cleavage is required for ENaC activation and controlled inhibition of this process
is vital for limiting Na+ absorption rates and for efficient ASL volume homeostasis (Fig. 4).
However, little is known about the physiological regulation of proteases and their inhibitors
in the airways, and their contribution to ENaC disregulation in chronic lung disease is only
now being fully appreciated. For example, unchecked activation of ENaC in CF airway
epithelia likely contributes to the depletion of ASL volume and impaired mucociliary clearance
in CF airways, yet the mechanism responsible for the protease– protease inhibitor imbalance
in CF airways remains uncertain (Fig. 4). Thus, a better understanding of this complex
regulatory process is warranted before we can develop effective treatments against ENaC
hyperabsorption in chronic lung disease.
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Cartoon representation of the structural model of the rat αENaC subunit. Each ENaC subunit
has two transmembrane regions, a large extracellular loop and a small “Pre-TM2” region (not
represented in the model) that may form part of the selectivity filter [126]. For all the subunits,
the C- and N-termini are intracellular. The sequence alignment for modeling the structure of
rat αENaC was generated by extending the one provided by Stockand et al. [135]. A portion
of the ‘hypervariable region’ was included in our alignment to account for the furin sites in
this model [135]. The structural model was generated using Medusa [42,163] with the crystal
structure of cASIC as the template [69]. Regions that do not have a template were modeled as
loops using Modeller [46]
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Proteolytic cleavage allows Na+ conduction through ENaC. ENaC is a heterotrimer consisting
of α, β, and γ subunits that together form the functional channel. a In the absence of proteolysis,
ENaC is uncleaved and cannot conduct Na+. b After proteolytic cleavage, the “inhibitory”
tracts from the extracellular loops of the α and γ subunits are removed, possibly leading to a
conformational change in the channel, which can now conduct Na+ (c)
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Speculation on ENaC proteolysis and how SPLUNC1 may inhibit this process. Uncleaved
ENaCs can be cleaved in the trans-Golgi network by furin. These cleaved ENaCs are then
transported to the plasma membrane in a highly regulated fashion (not shown, see [20,131])
where they are ready to conduct Na+. An additional pool of newly formed ENaCs are able to
bypass the furin cleavage step through an as-yet undetermined mechanism and directly inserted
into the plasma membrane as uncleaved, inactive “silent” channels. These silent ENaCs can
then be protetolytically cleaved by cell-attached, extracellular, channel-activating proteases
(CAPS) or by soluble proteases such as trypsin or human neutrophil elastase and converted
into active ENaC channels. Alternatively, silent ENaCs may bind to SPLUNC1, which is
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secreted from some epithelial cells in an autocrine/paracrine fashion. SPLUNC1 then triggers
the internalization of ENaC through an unknown process, making ENaC unavailable for
cleavage by CAPs or soluble proteases. Whether these internalized ENaCs continue to bind to
SPLUNC1 when internalized and whether they can be recycled to the plasma membrane or are
targeted for lysosomal degradation is not known
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ENaC and ASL volume regulation. a In normal airways under high volume conditions, which
may occur following glandular secretions, soluble inhibitors of ENaC proteolysis such as
SPLUNC1 or purinergic inhibitors such as adenosine or ATP may be diluted to such an extent
that ENaC is fully active, leading to Na+-led isotonic ASL absorption with Cl following through
the paracellular pathway. Most non-cleaved, silent ENaCs are likely to be converted to cleaved
active ENaCs by endogenous cell surface CAPs. Due to low levels of ATP and adenosine,
CFTR and TMEM16A (not shown) are inactive and no Cl secretion occurs. b As ASL volume
returns to steady-state levels, SPLUNC1 accumulates in the ASL in sufficient quantities to
prevent the conversion of silent ENaCs to active ENaCs and SPLUNC1 may also reduce
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surface ENaC levels. Adenosine also accumulates to sufficient levels to activate CFTR (likely
by stimulation of A2B adenosine receptors). This leads to a steady-state ASL height which
approximates the height of outstretched cilia (7 µm). c High ASL volume conditions may occur
in CF airways after inhalation of hypertonic saline. Under these conditions, Na+ absorption
dominates, as in normal airways. d However, as ASL volume is reduced in CF airways,
regulatory molecules such as SPLUNC1 are predicted to be ineffective at inhibiting ENaC,
leading to an inappropriate reduction in ASL volume. In the absence of CFTR, active A2BR
increases cAMP levels to stimulate rather than inactivate ENaC, further driving the reduction
in ASL volume. Thus, unlike NL airways, CF airways are unable to make the switch from an
absorbing to a secreting epithelia and ASL volume depletion results
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